These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36089530)

  • 21. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
    J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
    Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
    J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
    Grobet-Jeandin E; Pinar U; Rouprêt M
    Eur Urol Focus; 2022 Jul; 8(4):1121-1123. PubMed ID: 34544673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Step Closer to Predicting Progression After Bacillus Calmette-Guérin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
    Koti M; Robert Siemens D
    Eur Urol; 2023 Nov; 84(5):447-448. PubMed ID: 37400353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.
    Wang Z; So WZ; Loh KY; Lim YK; Mahendran R; Wu QH; Chiong E
    Int J Urol; 2022 Aug; 29(8):807-815. PubMed ID: 35598896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Maitre P; Sangar V; Choudhury A
    Eur Urol; 2023 Jun; 83(6):495-496. PubMed ID: 36898871
    [No Abstract]   [Full Text] [Related]  

  • 31. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
    Kates M; Chu X; Hahn N; Pietzak E; Smith A; Shevrin DH; Crispen P; Williams SB; Daneshmand S; Packiam VT; Porten S; Westerman ME; Wagner LI; Carducci M
    Eur Urol Focus; 2023 Jul; 9(4):561-563. PubMed ID: 37422371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
    Matsumoto K
    Int J Urol; 2022 Oct; 29(10):1130-1131. PubMed ID: 35686305
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
    Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
    Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
    Miyake M; Kikuchi E; Shinozaki K; Piao Y; Hayashi N; Koto R; Jinushi M; Kobayashi T
    Int J Urol; 2022 Oct; 29(10):1120-1129. PubMed ID: 35598101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
    de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
    J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
    Taoka R; Sugimoto M
    Int J Urol; 2022 Oct; 29(10):1130. PubMed ID: 35690471
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients.
    Chang SS
    J Urol; 2016 May; 195(5):1382. PubMed ID: 27186727
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.